← All stocks

Lyell Immunopharma, Inc.

LYEL Net buying

CIK 0001806952 #3374 in the set updated 17 Sep 2026

Bought (12 mo)

$25.00M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$604.59K

$274.30 on a plan · $0.00 straight out of an exercise

Sold at will

$604.31K

26 of 28 sales

Net

+$24.40M

+$24.40M against sales at will

By person

14 insiders · 30 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

ARCH Venture Fund XIII, L.P. entity

10% owner

$12.50M (1)

—

+$12.50M

1,426,528

$18.12M

+52.0%

ARCH Venture Partners IX, LLC entity

10% owner

$12.50M (1)

—

+$12.50M

1,426,528

$18.12M

+52.0%

Seely Lynn

President and CEO

—

$353.08K (6)

−$353.08K

63,899

$811.52K

—

Bulis Veronica Sanchez

VP, Corporate Controller

—

$96.91K (6)

−$96.91K

14,799

$187.95K

+56.6%

Lee Gary K.

Chief Scientific Officer

—

$71.69K (6)

−$71.69K

16,220

$205.99K

—

Hill Stephen J.

Chief Operating Officer

—

$51.29K (6)

−$51.29K

16,816

$213.56K

—

Shook David

Chief Medical Officer

—

$31.34K (2)

−$31.34K

20,423

$259.37K

+1,942%

Innovative Cellular Therapeutics Holdings Ltd entity

10% owner

—

$274.30 (2) scheduled

−$274.30

2,818,980

$35.80M

−7.4%

Klausner Richard

Director

—

843,365

$10.71M

+23.1%

Newton Charles W.

Chief Financial Officer

—

215,306

$2.73M

—

Ramachandra Sumant

Director

—

200,000

$2.54M

—

Lang Matthew

Chief Business Officer

—

162,500

$2.06M

+225.0%

BRAWLEY OTIS W

Director

—

35,640

$452.63K

—

Aguirre Jarrad Mattieu

Chief Medical Officer

—

20,279

$257.54K

0.0%

No percentages here. This company's share count has moved by a factor of 15.4 over the window, from 19,211,202 to 295,228,868 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Lyell Immunopharma, Inc.

By person

Individual transactions

What was left out